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Inhibition studies have suggested that acyl-CoA syn-
thetase (ACS, EC 6.2.1.3) isoforms might regulate the use
of acyl-CoAs by different metabolic pathways. In order
to determine whether the subcellular locations differed
for each of the three ACSs present in liver and whether
these isoforms were regulated independently, non-
cross-reacting peptide antibodies were raised against
ACS1, ACS4, and ACS5. ACS1 was identified in endoplas-
mic reticulum, mitochondria-associated membrane
(MAM), and cytosol, but not in mitochondria. ACS4 was
present primarily in MAM, and the 76-kDa ACS5 protein
was located in mitochondrial membrane. Consistent
with these locations, N-ethylmaleimide, an inhibitor of
ACS4, inhibited ACS activity 47% in MAM and 28% in
endoplasmic reticulum. Troglitazone, a second ACS4 in-
hibitor, inhibited ACS activity <10% in microsomes and
mitochondria and 45% in MAM. Triacsin C, a competi-
tive inhibitor of both ACS1 and ACS4, inhibited ACS
activity similarly in endoplasmic reticulum, MAM, and
mitochondria, suggesting that a hitherto unidentified
triacsin-sensitive ACS is present in mitochondria. ACS1,
ACS4, and ACS5 were regulated independently by fast-
ing and re-feeding. Fasting rats for 48 h resulted in a
decrease in ACS4 protein, and an increase in ACS5. Re-
feeding normal chow or a high sucrose diet for 24 h after
a 48-h fast increased both ACS1 and ACS4 protein ex-
pression 1.5–2.0-fold, consistent with inhibition studies.
These results suggest that ACS1 and ACS4 may be linked
to triacylglycerol synthesis. Taken together, the data
suggest that acyl-CoAs may be functionally channeled to
specific metabolic pathways through different ACS iso-
forms in unique subcellular locations.
The first step in long chain fatty acid use in mammals re-
quires the ligation of fatty acid with coenzyme A (CoA). This
reaction, catalyzed by acyl-CoA synthetase (ACS,1 EC 6.2.1.3),
produces acyl-CoAs, which are primary substrates for energy
use via b-oxidation and for the synthesis of triacylglycerol,
phospholipids, cholesterol esters, and sphingomyelin, and are
the source of signaling molecules like ceramide, diacylglycerol,
and arachidonic acid (1, 2). Acyl-CoAs up-regulate uncoupling
protein in brown fat and key enzymes of glycolysis, gluconeo-
genesis, and b-oxidation; are essential for vesicle trafficking;
and play a critical role in the transport of fatty acids into cells
by making transport unidirectional. Protein esterification with
myristate and palmitate anchors proteins to specific mem-
branes and enables them to function correctly (3). Thus, acyl-
CoAs participate in a large number of cellular reactions that
involve lipid synthesis, energy metabolism, and regulation, but
how acyl-CoAs are partitioned or directed toward these diverse
synthetic, degradative, and signaling pathways is not
understood.
Currently, five different rat ACS cDNAs have been cloned,
each the product of a different gene (4–8). Rat ACS1–5 share a
common structural architecture and are further classified into
two subfamilies based on amino acid identity and fatty acid
preference (4–8). ACS1, ACS2, and ACS5 make up one sub-
family with about 60% homology to one another, and ACS3 and
ACS4 make up a second subfamily with about 70% homology to
each other and 30% similarity to ACS1. Within each subfamily,
the ACS isoforms differ in their mRNA size, tissue distribution,
and transcriptional regulation. ACS1, ACS4, and ACS5 are all
expressed in liver.
Studies with the ACS inhibitors triacsin and troglitazone
suggested that long chain acyl-CoAs are functionally channeled
toward specific metabolic fates. In most of these studies, de
novo glycerolipid synthesis was severely inhibited, whereas
phospholipid reacylation and ketone bodies formation was less
impaired. Inhibition of fatty acid incorporation into cholesterol
esters varied with cell type, being completely blocked in human
fibroblasts and only moderately decreased in hepatocytes. For
example, in hepatocytes, triacsin C did not alter oxidation of
pre-labeled intracellular lipid, but did inhibit triacylglycerol
synthesis 40% and 70% in hepatocytes isolated from starved
and fed rats, respectively (9). Additionally, in hepatocytes iso-
lated from fasted rats, troglitazone blocked incorporation of
oleate into triacylglycerol, but not into phospholipid (10). In
addition, troglitazone inhibited ketone body production. In
human fibroblasts, triacsin C blocked the incorporation of
[3H]glycerol into phospholipid by 80% and the incorporation
into triacylglycerol by 99%, indicating severely impaired acy-
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lation of glycerol 3-phosphate, lysophosphatidic acid, and dia-
cylglycerol via the de novo synthetic pathway from glycerol
3-phosphate (11). Incorporation of [14C]oleate into triacylglyc-
erol was also blocked 95%, consistent with impaired acylation
via the de novo pathway; however, incorporation into phospho-
lipids was not impaired, suggesting that separate pools of acyl-
CoAs exist and that the reacylation pathway is functionally
separate from de novo glycerolipid synthesis. Taken as a whole,
these studies suggest that there are functionally independent
acyl-CoA pools within cells, and that acyl-CoAs might be chan-
neled toward specific fates rather than being freely available
for all possible enzymatic reactions.
Yeast provide clear evidence for functionally different ACS-
linked pathways. In Candida lipolytica, studies using ACS
mutants indicate that ACS I activates exogenous fatty acids for
glycerolipid synthesis and ACS II activates them for b-oxida-
tion (12). In Saccharomyces cerevisiae, the ACS proteins Faa1p
and Faa4p account for 99% of yeast C14-CoA and C16-CoA
activity (13) and activate exogenously derived fatty acids des-
tined for phospholipid synthesis (14). Faa4p is specifically
needed for myristoylation of protein substrates (15), and Faa2p
is required for peroxisomal b-oxidation (16, 17). Yeast ACS
isoforms are also differentially inhibited by triacsin C (18).
From these data, Gordon’s group (17) concluded that there are
differences in location or accessibility of those acyl-CoAs that
are derived from endogenous synthesis and those acyl-CoAs
formed from exogenously provided fatty acids. Thus, genetic
studies in yeast link specific ACS isoforms to different path-
ways that use acyl-CoAs.
We examined ACS1, ACS4, and ACS5 in rat liver, which
contains a variety of pathways that use acyl-CoAs, in order to
determine whether the subcellular locations, inhibition by spe-
cific inhibitors, and nutritional regulation might link the dif-
ferent ACS isoforms with different metabolic pathways. Our
data indicate that ACS1, ACS4, and ACS5 are present in dif-
ferent subcellular membranes; that ACS activity is inhibited by
triacsin C, troglitazone, and NEM to varying degrees in these
subcellular fractions; and that nutritional changes regulate
each ACS isoform independently.
EXPERIMENTAL PROCEDURES
Materials—[2-3H]Glycerol and [9,10-3H]palmitate were from Amer-
sham Pharmacia Biotech. Glycerol, palmitoyl-CoA, ATP, and bovine
serum albumin (essentially fatty acid-free) were from Sigma. Triacsin C
(.95% pure) was from Biomol. Troglitazone was the gift of Dr. Steven
Jacobs, GlaxoSmithKline. A polyclonal antibody to rat ACS1 was the
gift of Dr. Paul Watkins, Kennedy Krieger Institute.
Animals—Animal protocols were approved by the University of North
Carolina (UNC), Chapel Hill, NC and University of Alberta Institutional
Animal Care and Use Committees. Male and female (150 g) Harlan
Sprague-Dawley rats were housed on a 12-h/12-h light/dark cycle with
free access to water. Control animals had free access to Purina rat chow.
Fasted animals were sacrificed after being without food for 48 h. Refed
rats were sacrificed after being fed Purina rat chow or a high sucrose diet
(69.5% sucrose, Dyets, Inc.) for 24 h after a 48-h fast.
Subcellular Fractionation—For subcellular localization experiments,
liver cytosol, microsomes, rough and smooth endoplasmic reticulum,
mitochondria-associated membrane (MAM), and mitochondria were iso-
lated from male rats by a method (19) modified by Vance (20). Liver
total membrane fraction, microsomes, and mitochondria were isolated
from female rats by differential centrifugation (21) in the presence of
protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leu-
peptin, and 1 mg/ml pepstatin) for subcellular localization and nutri-
tional regulation experiments. Fractions were stored in aliquots at
280 °C. Protein concentrations were determined by the BCA method
(Pierce) using bovine serum albumin as the standard.
Immunoblotting—Peptides corresponding to regions of rat ACS1,
ACS4, and ACS5 that show poor amino acid conservation (ACS1,
MEVHELFRYFRMPELIDIR; ACS4, EIHSMQSVEELGSKPENSSI;
ACS5, KCGIEMLSLHDAENL) were synthesized, purified, and coupled
to keyhole limpet hemocyanin in the UNC/PMBB Micro Protein Chem-
istry Facility. Rabbit antibodies to these peptides and to purified mito-
chondrial GPAT were raised commercially in New Zealand White rab-
bits (ImmunoDynamics, La Jolla, CA). Antibodies to PEMT2 were made
as described previously (22). Proteins were separated on an 8% (or 12%
for PEMT2) polyacrylamide gel containing 1% SDS and transferred to a
polyvinylidene difluoride membrane (Bio-Rad). For chemiluminescent
detection, the immunoreactive bands were visualized by incubating the
membrane with horseradish peroxidase-conjugated goat anti-rabbit
IgG and PicoWest reagents (Pierce). For quantitation, the polyvinyli-
dene difluoride membrane was incubated with 0.5 m Ci of 125I-Protein A
(ICN), exposed to a phosphor screen, and quantified with the Molecular
Dynamics Storm 840 and ImageQuant software.
Enzyme Assays—Diacylglycerol acyltransferase was assayed at 23 °C
with 200 mM sn-1,2-diolein and 25 mM [3H]palmitoyl-CoA (23), acyl-CoA
synthetase was assayed at 37 °C with 5 mM ATP, 250 mM CoA, and 50
mM [3H]palmitate (24), and glycerol 3-phosphate acyltransferase
(GPAT) was assayed at 23 °C with 300 mM [3H]glycerol-3-P and 112.5
mM palmitoyl-CoA in the presence or absence of 2 mM N-ethylmaleimide
to inhibit the microsomal isoform (25). Microsomal GPAT was esti-
mated by subtracting the N-ethylmaleimide-resistant activity (mito-
chondrial GPAT) from the total. All assays measured initial rates.
[3H]Palmitoyl-CoA (26) and [3H]glycerol 3-phosphate (27) were synthe-
sized enzymatically.
RESULTS
ACS1, ACS4, and ACS5 Are Located in Different Subcellular
Fractions—The relative distribution of ACS activity in rat liver
is 7% in peroxisomes, 20% in mitochondria, and 73% in micro-
somes (28). Since measurements of ACS activity do not distin-
guish among the different ACS isoforms, we localized each
isoform in order to determine whether it is evenly distributed
or, instead, located in a specific subcellular membrane.
We raised isoform-specific rabbit antibodies against unique
peptides present in ACS1, ACS4, or ACS5 because an antibody
raised against purified ACS1 not only recognized purified re-
combinant ACS1, but also recognized purified recombinant
ACS4 and ACS5 (Fig. 1A). The cross-reactivity is most likely
FIG. 1. Specificity of ACS1, ACS4, and ACS5 antibodies. Purified recombinant ACS1, ACS4, or ACS5, each with a C-terminal Flag epitope
(5 mg of total protein), were analyzed by Western blot with antibodies raised against full-length ACS1 (A) or unique peptides from ACS1 (B), ACS4
(C), ACS5 (D), or the Flag epitope (E). The MC lane represents liver microsomes blotted with ACS1 peptide antibody. Protein antibody complexes
were visualized by chemiluminescent detection of horseradish peroxidase linked to goat anti-rabbit or anti-mouse IgG. The molecular mass values
of recombinant ACS1, ACS4, and ACS5 were 68, 74, and 76 kDa, respectively, on this gel system.
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due to the high degree of sequence similarity found among
ACS1, ACS4, and ACS5. The specificity of each of our peptide
antibodies was verified by immunoblot analysis of each isoform
specific antibody against purified recombinant rat ACS1,
ACS4, and ACS5, each with a C-terminal Flag epitope (29).
Peptide antibodies for ACS4 and ACS5 each recognized only
the correct ACS isoform (Fig. 1, C and D). The ACS1 peptide
antibody failed to recognize recombinant ACS1-Flag (Fig. 1B)
because the initial two amino acids of the N-terminal sequence
had been altered to clone the recombinant protein. However,
the recombinant ACS1-Flag protein detected by the Flag anti-
body and the major band in rat liver microsomes detected by
the ACS1 peptide antibody migrate to the same position, show-
ing that the ACS1 peptide antibody recognizes native ACS1
(Fig. 1E).
Rat liver was fractionated by two different methods. One
method used a sucrose gradient to further purify microsomes
into ER1 and ER2 fractions that are enriched in rough and
smooth ER, respectively (19, 20). A Percoll gradient sepa-
rated crude mitochondria into MAM and purified mitochon-
dria (19, 20). The second method used only differential cen-
trifugation (21) and produced mitochondria that had very
little microsomal contamination and microsomes that pri-
marily contained ER membranes, as well as the MAM frac-
tion. The purity of each fraction was ascertained by enzy-
matic assays for the ER enzymes DGAT and NEM-sensitive
GPAT, and for the mitochondrial enzyme NEM-resistant
GPAT and an by immunoblots for mitochondrial GPAT and
for PEMT, the MAM marker. These markers showed that the
microsome fraction was free of mitochondrial contamination
because little NEM-resistant GPAT activity was present (Ta-
ble I) and no mitochondrial GPAT protein was detected by
immunoblotting (Fig. 2B). In the ER and MAM fractions
purified using gradients, 11–28% of the GPAT activity was
resistant to NEM (Table I), indicating that these fractions
were somewhat contaminated with mitochondria. No PEMT
was detected in the ER and purified mitochondria by immu-
noblot analysis (Fig. 2B), indicating that these fractions were
not contaminated with the MAM fraction. Very low DGAT
and NEM-sensitive GPAT activities were measured in the
purified mitochondria (Table I), indicating little contamina-
tion with ER. DGAT activity was enriched in the MAM frac-
tion compared with ER, consistent with previous results (40).
The microsome fraction (100,000 3 g pellet) also has high
DGAT activity, and it contains the MAM fraction, as evi-
denced by the presence of the MAM-specific marker, PEMT
(Fig. 2B).
The location of ACS1, ACS4, and ACS5 in rat liver was
determined by Western blot analysis of various subcellular
fractions. ACS1 (68 kDa) was strongly detected in the micro-
somal fraction, which comprises rough ER, smooth ER, and
MAM (Fig. 2A). The molecular mass is smaller than that pre-
dicted by the cDNA sequence (78 kDa), but in agreement with
the size of the recombinant ACS1 run in the same manner (Fig.
1). A prominent ACS1 band was also detected in the cytosol,
but cytosolic ACS specific activity was only 2.6% that of micro-
somal ACS specific activity (3.5 versus 132 nmol/min/mg of
protein). Although ACS1 was present in crude mitochondria,
which contain the MAM fraction, no ACS1 band was observed
in purified mitochondria (Fig. 2A), as we reported previously
(9). ACS4 (74 kDa) was enriched in the MAM fractions from rat
liver (Fig. 2A) and Chinese hamster ovary cells (data not
shown), and was only very weakly detected in microsomal and
mitochondrial fractions. In some preparations, ACS4 was de-
tected as a doublet with a larger 75-kDa protein (data not
shown), consistent with alternative start sites as described for
the human ACS4 homologue (30). The ACS5-specific antiserum
detected a protein of 76 kDa in the mitochondrial fraction (Fig.
2A), 73- and 74.5-kDa proteins in ER, and a 74.5-kDa protein in
cytosol and MAM fractions (Fig. 2A). The 76-kDa protein
agrees with the size predicted by the cDNA sequence and
migrates to the same position as recombinant ACS5. Taken
together, these data indicate that ACS1, ACS4, and ACS5 each
have unique distributions in liver subcellular membranes.
Inhibition of ACS Activity in Liver Subcellular Fractions—
Since ACS1, ACS4, and ACS5 were present in different subcel-
lular membranes and the recombinant proteins expressed in
Escherichia coli were inhibited to different extents by triacsin
FIG. 2. Location of ACS1, ACS4, and ACS5 in rat liver subcel-
lular fractions. Cytosol (C), microsomes (MC), fractions enriched in
smooth endoplasmic reticulum (SER), fractions enriched in rough en-
doplasmic reticulum (RER), MAM, crude mitochondria (cMT), and pure
mitochondria (pMT) fractions (100 mg of protein) were analyzed by
Western blot with antibodies against ACS1, ACS4, or ACS5 (A) and
GPAT or PEMT (B) . Molecular mass is indicated on the right.
TABLE I
DGAT and GPAT activity in liver subcellular fractions
Specific activity nmol/min/mg (n 5 3)
DGAT GPATa Mitochondrial GPATb
Microsomesc 1.72 6 0.22 1.27 6 0.16 0.06 6 0.01 (4.7%)d
ER1e 0.31 6 0.15 2.35 6 0.23 0.51 6 0.19 (22%)d
ER2e 0.59 6 0.19 1.41 6 0.09 0.29 6 0.02 (20%)d
MAMf 0.94 6 0.07 2.05 6 0.35 0.61 6 0.32 (30%)d
Crude mitochondriag 0.38 6 0.09 1.20 6 0.07 0.64 6 0.05 (54%)d
Pure mitochondriaf 0.19 6 0.13 1.10 6 0.35 1.00 6 0.22 (91%)d
a GPAT specific activity assayed in the absence of NEM.
b Remaining GPAT activity following treatment of sample with 2 mM NEM.
c 100,000 3 g pellet from supernatant fraction after isolation of crude mitochondria.
d Percent of GPAT specific activity assayed in the absence of NEM.
e Fraction isolated from sucrose gradient.
f Fraction isolated from Percoll gradient.
g 10,000 3 g pellet.
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C, thiazolidinediones, and NEM (29), we hypothesized that
these inhibitors would affect ACS activity differently in each
fraction. Triacsin C (10 mM), which inhibits purified recombi-
nant ACS1 and ACS4 by 60%, and does not inhibit ACS5 (29),
decreased ACS activity in microsomes, mitochondria, and
MAM by 60% (Fig. 3). This result is surprising because the only
ACS we identified in mitochondria was ACS5, which is resist-
ant to inhibition by triacsin C (29). The mitochondria we as-
sayed were free of contamination by the MAM fraction as
determined by the absence of PEMT on an immunoblot (data not
shown). Therefore, the observed inhibition suggests that mitochon-
dria contain a hitherto undescribed triacsin-sensitive ACS.
Troglitazone and NEM, two specific ACS4 inhibitors, were
more selective inhibitors of ACS activity in liver subcellular
fractions. Troglitazone at 10 mM decreased ACS activity 25% in
MAM, but had no effect on activity in the microsomal or mito-
chondrial fractions (Fig. 4). With 50 mM troglitazone, ACS ac-
tivity was inhibited 45% in MAM, again with little effect on
microsomal or mitochondrial ACS activity. NEM, a second
ACS4 inhibitor, decreased ACS activity 50% in MAM and only
27% in the smooth ER fraction (Fig. 5). These results are
consistent with the immunolocalization of ACS4 preferentially
to the MAM fraction.
Nutritional Regulation of ACS1, ACS4, and ACS5 in Liv-
er—If ACS1, ACS4, and ACS5 are linked to different metabolic
pathways, one might expect that each isoform would be regu-
lated differently under conditions of fasting and re-feeding.
ACS activity and protein expression were measured in liver
microsomes and mitochondria isolated by differential centrifu-
gation from control rats, from rats fasted for 48 h, and from rats
fasted for 48 h and then refed either Purina rat chow or a high
sucrose diet for 24 h. The microsomes contained MAM, and the
mitochondria were free of contamination by MAM as deter-
mined by immunoblot with antibody against PEMT, the MAM-
specific marker (data not shown). ACS activity, assayed with
palmitate as the fatty acid substrate, was similar in micro-
somes and in mitochondria isolated from control rats (18.5 63.5
and 14.3 6 2.9, respectively), 48-h fasted rats (21.8 6 0.9 and
11.9 6 2.9, respectively), and rats fed Purina rat chow for 24 h
after a 48-h fast (15.1 6 4.5 and 14.2 6 2.4, respectively).
Although total ACS activity was unchanged by nutritional
status, ACS1 protein expression increased 1.8- and 2-fold with
Purina chow and high sucrose re-feeding, respectively (Fig. 6).
ACS4 protein expression also increased with re-feeding (50%
FIG. 3. Triacsin C inhibits ACS activity in microsomes, smooth
ER, mitochondria, and mitochondria-associated membrane
fractions. Microsomes, ER1 (enriched in rough ER), mitochondria, or
MAM proteins (0.5 mg) were assayed for ACS activity in the presence of
increasing concentrations of triacsin C (0–10 mM). Data are represent-
ative of two independent experiments and are presented as percentage
of ACS activity remaining after treatment with inhibitor. Control spe-
cific activities (100%): microsomes 5 109 nmol/min/mg; ER1 5 211
nmol/min/mg; mitochondria 5 105 nmol/min/mg; MAM 5 345
nmol/min/mg.
FIG. 4. Troglitazone specifically inhibits ACS activity in mito-
chondria-associated membrane. Microsomes, mitochondria, or
MAM proteins (0.5 mg) were assayed for ACS activity in the presence of
increasing concentrations of troglitazone (0–50 mM). Data are repre-
sentative of two independent experiments and are presented as per-
centage of ACS activity remaining after treatment with inhibitor. Con-
trol specific activities (100%): microsomes 5 89 nmol/min/mg;
mitochondria 5 67 nmol/min/mg; MAM 5 255 nmol/min/mg.
FIG. 5. N-Ethylmaleimide inhibits ACS activity in mitochon-
dria-associated membrane. ER1 (enriched in rough ER) and MAM
fractions (0.5–1.5 mg of protein) were pre-incubated in the absence or
presence of 5 mM NEM for 10 min on ice prior to ACS assay. Control
specific activities (100%): ER1 5 181 nmol/min/mg; MAM 5 397
nmol/min/mg.
FIG. 6. ACS1, ACS4, and ACS5 protein expression is regulated
differently by fasting and re-feeding. Liver total microsomes and
mitochondria (100 mg of protein) from rats fed normally (N) (n 5 5),
fasted for 48 h (F) (n 5 6), fasted for 48 h and refed normal chow for 24 h
(R) (n 5 6), and fasted for 48 h and refed a 69% sucrose diet for 24 h (S)
(n 5 4) were analyzed by quantitative Western blot analysis with
peptide antibodies against ACS1, ACS4, or ACS5 and 125I-Protein A.
The blots were exposed to a phosphor screen for quantitation with a
Molecular Dynamics Storm 840 system. The blots shown are represent-
ative, and the numbers below the bands indicate the -fold change
compared with normally fed rats. The mean and S.D. for each are as
follows: ACS1, N (1 6 0.05), F (0.8 6 0.05), R (1.8 6 0.1), S (1.9 6 0.02);
ACS4, N (1 6 0.08), F (0.5 6 0.07), R (1.6 6 0.15), S (2 6 0.12); ACS5,
N (1 6 0.04), F (1.8 6 0.05), R (1.2 6 0.1), S (1 6 0.06).
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with Purina chow diet and 64% with sucrose diet). ACS5 pro-
tein expression in mitochondria did not appear to be altered by
re-feeding. After a 48-h fast, ACS1 protein expression de-
creased 14%, ACS4 protein decreased 47%, whereas ACS5 pro-
tein expression increased 82% in mitochondria (Fig. 6).
DISCUSSION
Long chain acyl-CoA synthetase catalyzes the initial step
required for oxidation, elongation, and desaturation of fatty
acids; for the synthesis of complex lipids and acylated proteins;
and for a variety of signals that regulate cellular metabolism
(1, 2). It had been thought that the ACSs synthesize a common
pool of acyl-CoAs, which move freely within cell membrane
monolayers and have equal access to the numerous metabolic
pathways in which they participate. However, genetic studies
in yeast link specific ACS isoforms to different pathways that
use acyl-CoAs (12–17). In addition, in cultured cells, inhibitors
of ACS (triacsin and troglitazone) selectively alter the synthe-
sis and oxidation of cellular lipids, suggesting that the ACS
isoforms might be differentially inhibited, and that triacsin-
sensitive isoforms might be functionally linked to de novo glyc-
erolipid synthesis whereas triacsin-resistant ACS isoforms
might be functionally linked to phospholipid reacylation path-
ways and to b-oxidation (9–11, 31–33). These data, together
with our results showing that triacsin C inhibits recombinant
ACS1 and ACS4, but not ACS5, and that thiazolidinediones
specifically inhibit ACS4 (29), suggested that acyl-CoA entry
into specific metabolic pathways could be mediated by the
action of individual ACS isoforms.
In this paper, we show that ACS1, ACS4, and ACS5 differ in
their subcellular distribution, suggesting that, as in yeast,
acyl-CoAs may be channeled toward specific metabolic path-
ways. Functional channeling could occur if a particular ACS
were located in a membrane that contained only a handful of
specific pathways that use acyl-CoAs or if each ACS were
physically associated with the downstream enzymes in a spe-
cific pathway. To examine this question, we investigated the
subcellular locations of the three ACSs expressed in rat liver.
ACS1, the first cloned and best studied ACS isoform, has been
reported to be present in virtually every subcellular fraction.
An early study with a polyclonal antibody raised against ACS1
purified from microsomes reported that ACS1 protein was pres-
ent in rat liver microsomes, peroxisomes, and mitochondria
(34). Others have identified ACS1 in GLUT4 vesicles (35) and
in plasma membrane (36) from fat cells. ACS activity has been
reported in nuclei from rat liver (37), and in cytosol of PC12
neurons (38), but the ACS isoform was not determined in either
case. Our studies showed ACS1 protein in the microsomal
fraction of rat liver. ACS1 does not appear to contribute to the
ACS activity present in mitochondria, since our peptide anti-
body did not detect ACS1 in purified mitochondria under any
nutritional condition, consistent with our previous study (9).
Although ACS1 had been identified in rat mitochondria with
an antibody raised against an ACS purified from microsomes
(34), the antibody may have recognized epitopes on non-ACS1
isoforms present in mitochondrial membranes as we showed in
Fig. 1.
We also detected a significant amount of ACS1 protein in rat
liver cytosol. Although a cytosolic location is consistent with
measurements of oleic acid ACS activity in the cytosol of PC12
cells, ACS activity and ACS1 protein expression are absent in
the cytosol from 3T3-L1 adipocytes (36). Since, in liver cytosol,
ACS specific activity was barely detectable, our antibody may
cross-react with a non-ACS cytosolic protein of the same mo-
lecular mass. Alternatively, cytosolic ACS1 may be largely
inactive, but become active after it translocates to intracellular
membranes as occurs with oleate-activated FadD, the bacterial
ACS (39).
The subcellular locations of ACS4 and ACS5 have not been
reported previously. Some of the mitochondrial ACS activity is
accounted for by ACS5, since we detect a 76-kDa protein (in
agreement with the predicted size of ACS5) specifically in
mitochondria. The ACS5 peptide antibody also detects 73- and
74.5-kDa proteins in ER and MAM, and a 74.5-kDa protein in
cytosol and MAM fractions. Both ACS3 and ACS4 can use
alternative start sites (6, 30), but no alternative start site is
present in the ACS5 sequence that would yield proteins smaller
by 1.5 or 3 kDa. The smaller immunoreactive proteins might
represent ACS5 after proteolytic cleavage, or it may be that the
ACS5 peptide antibody recognizes a novel ACS isoform with a
high degree of sequence similarity.
ACS4 is highly enriched in the MAM fraction, an ER-like
membrane that can be found in mitochondria or ER prepara-
tions, depending on the cell fractionation method employed.
The MAM fraction contains PEMT-2, microsomal triglyceride
transfer protein, apoB, and high specific activities of acyl-CoA:
cholesterol acyltransferase, DGAT (40), and phosphatidyl-
serine synthase-1 and -2 (41). Vance’s group has hypothesized
that MAM may be involved in importing lipids into mitochon-
dria (42) or in very low density lipoprotein assembly (40).
Inhibition studies with purified ACS1, ACS4, and ACS5
showed that triacsin C inhibited only ACS1 and ACS4, whereas
the thiazolidinediones and NEM were more selective and only
inhibited ACS4 (29). Consistent with these inhibition studies
and the location of the three isoforms in liver, troglitazone and
NEM had their maximum effects in MAM where ACS4 is
located. Similarly, triacsin C was a potent inhibitor of ACS
activity in ER and MAM, membranes that contain both ACS1
and ACS4. Surprisingly, however, triacsin C inhibited ACS
activity in mitochondria to the same extent that it inhibited
activity in ER (Fig. 2). Since the triacsin-resistant ACS5 is the
only ACS isoform detected in mitochondria, a hitherto un-
known triacsin-sensitive ACS may be present in mitochondria.
Another possibility is that purified ACS5-Flag, which is not
inhibited by triacsin, does not have the same properties as the
in situ enzyme. We do not believe that this is the case, since the
Flag epitope does not interfere with ACS activity (29) and
triacsin C is unable to inhibit ACS activity in an E. coli mem-
brane fraction containing overexpressed ACS5-Flag (data not
shown).
Because MAM may be a specialized site for very low density
lipoprotein biosynthesis, the presence of ACS4 in this fraction
and its inhibition by triacsin C suggests that ACS4, like ACS1,
is linked to triacylglycerol synthesis. Consistent with this hy-
pothesis, we found that ACS4 protein expression decreased
47% after a 48-h fast, and was up-regulated by re-feeding
either normal chow (50% increase) or a high sucrose diet (64%
increase). The most remarkable finding was the specific inhi-
bition of recombinant ACS4 by thiazolidinediones (29) and the
ability of troglitazone to specifically inhibit ACS activity in
MAM (Fig. 3). It has been hypothesized that the mechanism by
which thiazolidinediones produce their anti-diabetic effects is
through their ability to lower plasma fatty acids (43). Further study
is needed to determine whether thiazolidinediones are insulin sen-
sitizers, in part, because of their inhibitory effect on ACS4.
In humans, the gene for ACS4 lies on the X chromosome and
is part of a large deletion that results in a human disorder that
combines Alport syndrome with elliptocytosis, dysmorphic fa-
cies, and mental retardation (44). It is not known whether the
deleted ACS4 contributes to these problems or whether the
disorder is associated with abnormalities in serum lipids. How-
ever, since expression of ACS4 is highest in human brain, and
human and rat ACS4 show a preference for arachidonate, it has
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been suggested that, in brain, ACS4 might be critical for recy-
cling arachidonate into phospholipids that are sources for sig-
naling molecules related to intellect and coordination (30).
Consistent with its microsomal location and the powerful
triacsin-mediated inhibition of triacylglycerol synthesis in fi-
broblasts, hepatocytes, and HepG2 cells (11, 31–33), ACS1 has
been linked to triacylglycerol synthesis. ACS1 mRNA is prom-
inent in liver and adipose tissue (4), and in 3T3-L1 cells only
after they differentiate into adipocytes (45). ACS1 mRNA ex-
pression also increases in adipose tissue and muscle after
PPARg activation (46), and in liver after high dietary fat re-
feeding (4). The presence of ACS1 in GLUT1 vesicles is hypoth-
esized to be linked to vesicle trafficking, which requires palmi-
toyl-CoA (35), but ACS1 could, in fact, function to increase fatty
entry into cells in response to insulin stimulation. On the other
hand, liver ACS1 is regulated by PPARa (46–48), whose acti-
vation is usually associated with the up-regulation of enzymes
of fatty acid oxidation. Our finding that ACS1 is present in ER,
MAM, and possibly peroxisomes2 provides a potential explana-
tion, if the various physiological processes result in changes in
the amount of ACS1 protein present in different subcellular
organelles (e.g. peroxisomes versus ER). In fact, reciprocal dif-
ferences in ACS activity were observed in mitochondria and
microsomes after stimulation by cytokines, but, unfortunately,
the ACS isoforms involved were not identified (49).
ACS5 may be linked to the b-oxidation pathway because its
protein expression increased 80% after a 48-h fast. This in-
crease in ACS5 protein contrasts with a previous study that
reported a 50% decrease in ACS5 mRNA after a fast (8). It is
possible that the rate of ACS5 protein turnover is decreased in
response to fasting. Although the presence of a triacsin-sensi-
tive ACS linked to b-oxidation is consistent with previous ob-
servations that treatment of hepatocytes with triacsin C (10
mM) results in a 30% decrease in acid soluble metabolites (9),
because recombinant ACS5 is not sensitive to triacsin (29),
there must be a novel triacsin-sensitive ACS in mitochondria.
Many unique eukaryotic enzymes catalyze the same lipid-
biosynthetic reaction (50). These enzymes are encoded by dif-
ferent genes and are often located in distinct cellular locations.
Our findings show that ACS1, ACS4, and ACS5 are located in
different liver subcellular membranes and that nutritional
changes regulate each isoform independently, consistent with
the hypothesis that eukaryotic systems have redundant lipid-
biosynthetic enzymes in order to provide independent regula-
tion of activity and compartmentalization of lipid pools (50).
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